Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its application in a bioequivalence study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 83, Issue , 2013, Pages 101-107

  Zhou, Ying ^a   Li, Jie ^a   He, Xiaomeng ^a   Jia, Mengmeng ^a   Liu, Mingzhou ^b   Li, Huqun ^a   Xiong, Zhengjiang ^c   Fan, Yue ^d   Li, Weiyong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN POLYTECHNIC UNIVERSITY   (China)

^c Lunan Pharmaceutical Group Corporation   (China)

^d HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Amlodipine; Atorvastatin; Bioequivalence; Liquid chromatography tandem mass spectrometry; Metabolites

Indexed keywords

2 HYDROXY ATORVASTATIN; 4 HYDROXY ATORVASTATIN; ACETIC ACID ETHYL ESTER; ACETONITRILE; AMLODIPINE; AMMONIUM ACETATE; ATORVASTATIN; DRUG METABOLITE; FORMIC ACID; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

AMLODIPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEPTANOIC ACIDS; HUMANS; LIQUID-LIQUID EXTRACTION; MALE; PYRROLES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 84878441122     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.04.021     Document Type: Article

References (23)

1. Gu D.F., Gupta A.J.L., Muntner P., Hu S.S., Duan X.F., Chen J.C., Reynolds R.F., Whelton P.K., He J. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation 2005, 112:658-665.
2. Asmar R., Vol S., Pannier B., Brisac A.M., Tichet J., El Hasnaoui A. High blood pressure and associated cardiovascular risk factors in France. J. Hypertens. 2001, 19:1727-1732.
3. Thomas F., Bean K., Guize L., Quentzel S., Argyriadis P., Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (55 years) men and women. Eur. Heart J. 2002, 23:528-535.
4. Zamorano J., Edwards J. Combining antihypertensive and antihyperlipidemic agents-optimizing cardiovascular risk factor management. Integr. Blood Press. Control 2011, 4:55-71.
5. Haria M., Wagstaff A.J., Amlodipine A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995, 50:560-586.
6. Malhotra H.S., Goa K.L. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001, 61:1835-1881.
7. Chung M., Calcagni A., Glue P., Bramson C. Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J. Clin. Pharmacol. 2006, 46:1030-1037.
8. Chung M., Calcagni A., Glue P., Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J. Clin. Pharmacol. 2006, 46:1212-1216.
9. Messerli F.H., Bakris G.L., Ferrera R.D., Houston M.C., Petrella R.J., Flack J.M., Sun W., Lee E.M. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J. Clin. Hypertens. 2006, 8:571-581.
10. Preston R.A., Harvey P., Herfert O., Dykstra G., Jukema J.W., Sun F., Gillen D. A randomized, placebo controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J. Clin. Pharmacol. 2007, 47:1555-1569.
11. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 2003, 42:1141-1160.
12. Liu Y.M., Pu H.H., Liu G.Y., Jia J.Y., Weng L.P., Xu R.J., Li G.X., Wang W., Zhang M.Q., Lu C., Yu Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Clin. Ther. 2010, 32:1396-1407.
13. Jacobsen W., Kuhn B., Soldner A., Kirchner G., Sewing K.F., Kollman P.A., Benet L.Z., Christians U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 2000, 28:1369-1378.
14. Nirogi R.V.S., Kandikere V.N., Shukla M., Mudigonda K., Maurya S., Boosi R., Anjaneyulu Y. Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomed. Chromatogr. 2006, 20:924-936.
15. Erk N. Extractive spectrophotometric determination of atorvastatin in bulk and pharmaceutical formulations. Anal. Lett. 2003, 36:2699-2711.
16. Shen H.R., Liz D., Zhong M.K. HPLC assay and pharmacokinetic study of atorvastatin in beagle dog after oral administration of atorvastatin self-microemulsifying drug delivery system. Pharmazie 2006, 61:18-20.
17. Erturk S., Aktas E.S., Ersoy L., Ficicioglu S. A HPLC method for the determination of atorvastatin and its impurities in bulk drugs and tablets. J. Pharm. Biomed. Anal. 2003, 33:1017-1023.
18. Chaudhri B.G., Patel N.M., Shah P.B. Simultaneous estimation of atorvastatin calcium and amlodipine besylate by HPTLC. Indian Drugs 2006, 43:649-655.
19. Shah D.A., Bhatt K.K., Mehta R.S., Baldania S.L., Gandhi T.R. Stability indicating RP-HPLC estimation of atorvastatin calcium and amlodipine besylate in pharmaceutical formulations. Indian J. Pharm. Sci. 2008, 70:754-760.
20. Liu D.Y., Ji J., Hui Z., Hu P. Quantitative determination of atorvastatin and para-hydroxy atorvastatin in human plasma by LC-MS-MS. J. Chromatogr. Sci. 2008, 46:862-866.
21. Ravi V.B., Mullangi R., Inamadugu J.K., Pilli N.R., Gajula R., Ponneri V. Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomed. Chromatogr. 2012, 26:1436-1443.
22. Pilli N.R., Inamadugu J.K., Mullangi R., Karra V.K., Vaidya J.R., Rao J.V. Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomed. Chromatogr. 2011, 25:439-449.
23. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) May 2001.